Search

everythinglearnresearchcommunity

for

Search:↓

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Patients with advanced breast cancer and high hormone receptor levels who had surgery for ovarian/pelvic metastases lived longer, especially if they had high estrogen receptor levels.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Many adult women experience unexplained excessive hair shedding, often starting before age 40.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

Low intensity ultrasound may reduce side effects of chemotherapy drugs like paclitaxel.

Taxane-based chemotherapy causes more hair loss and skin changes in Asian breast cancer patients.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

More research is needed to understand chemotherapy-induced hair loss and its phases.

Most patients treated with trastuzumab and paclitaxel experience some hair loss, but it's usually not severe.

A woman with low thyroid function did not lose her hair during chemotherapy, possibly because her hair follicles were less affected by the treatment.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

The new nanoparticles could improve melanoma treatment by working better than current options.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.

The treatment is safe and shows promise for metastatic breast cancer.

Chemotherapy causes hair loss by damaging hair follicles and stem cells, with more research needed for prevention and treatment.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Low dose oral minoxidil helps regrow hair in permanent chemotherapy-induced alopecia.

Some drugs used to treat inflammation may cause hair loss.

Permanent hair loss after bone marrow transplant can be caused by chemotherapy or chronic graft-versus-host disease.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

Chemotherapy caused a woman's permanent hair loss and early menopause.

The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Sex hormones might influence bladder cancer development, and aromatase inhibitors could increase risk in postmenopausal women.

Scalp hypothermia can prevent chemotherapy-induced hair loss but is not suitable for all patients, and more research is needed to improve prevention methods.